RS50165B - Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema - Google Patents

Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema

Info

Publication number
RS50165B
RS50165B YUP-290/02A YUP29002A RS50165B RS 50165 B RS50165 B RS 50165B YU P29002 A YUP29002 A YU P29002A RS 50165 B RS50165 B RS 50165B
Authority
RS
Serbia
Prior art keywords
alkyl
carbons
hydrogen
group
formula
Prior art date
Application number
YUP-290/02A
Other languages
English (en)
Serbian (sr)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
F. Hoffmann-La Roche Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag., filed Critical F. Hoffmann-La Roche Ag.,
Publication of YU29002A publication Critical patent/YU29002A/sh
Publication of RS50165B publication Critical patent/RS50165B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YUP-290/02A 1999-10-19 2000-10-13 Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema RS50165B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (2)

Publication Number Publication Date
YU29002A YU29002A (sh) 2005-06-10
RS50165B true RS50165B (sr) 2009-05-06

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-290/02A RS50165B (sr) 1999-10-19 2000-10-13 Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema

Country Status (33)

Country Link
US (1) US6300350B1 (https=)
EP (1) EP1225878B1 (https=)
JP (2) JP4074458B2 (https=)
KR (1) KR100485581B1 (https=)
CN (1) CN1201730C (https=)
AR (1) AR029648A1 (https=)
AT (1) ATE344661T1 (https=)
AU (1) AU777325B2 (https=)
BR (1) BR0015225A (https=)
CA (1) CA2387844C (https=)
CY (1) CY1105941T1 (https=)
CZ (1) CZ20021657A3 (https=)
DE (1) DE60031790T2 (https=)
DK (1) DK1225878T3 (https=)
ES (1) ES2274810T3 (https=)
HR (1) HRP20020329A2 (https=)
HU (1) HUP0203295A3 (https=)
IL (1) IL149151A0 (https=)
JO (1) JO2178B1 (https=)
MA (1) MA26835A1 (https=)
MX (1) MXPA02003843A (https=)
MY (1) MY129001A (https=)
NO (1) NO328738B1 (https=)
NZ (1) NZ518118A (https=)
PE (1) PE20010678A1 (https=)
PL (1) PL357499A1 (https=)
PT (1) PT1225878E (https=)
RS (1) RS50165B (https=)
RU (1) RU2257383C2 (https=)
TR (1) TR200201071T2 (https=)
TW (1) TWI288639B (https=)
WO (1) WO2001030326A1 (https=)
ZA (1) ZA200202576B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
BR0212583A (pt) * 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
EP1430023B1 (en) 2001-09-18 2009-04-08 F. Hoffmann-La Roche Ag Substituied urea retinoid agonists ii
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US20140155381A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
SG10201708931XA (en) 2012-12-17 2017-12-28 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
ES2212797T3 (es) * 1993-08-19 2004-08-01 Janssen Pharmaceutica N.V. Derivados de dihidrobenzopirano vasoconstrictores.
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
DK0728742T3 (da) * 1995-02-24 2000-04-17 Hoffmann La Roche Hidtil ukendte retinoider
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
EP1030662B1 (en) * 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
MXPA02000828A (es) * 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
NO328738B1 (no) 2010-05-03
MA26835A1 (fr) 2004-12-20
KR100485581B1 (ko) 2005-04-27
HK1051002A1 (en) 2003-07-18
TR200201071T2 (tr) 2002-08-21
ES2274810T3 (es) 2007-06-01
PT1225878E (pt) 2007-01-31
YU29002A (sh) 2005-06-10
ATE344661T1 (de) 2006-11-15
HRP20020329A2 (en) 2004-04-30
TWI288639B (en) 2007-10-21
HUP0203295A3 (en) 2003-04-28
KR20020043640A (ko) 2002-06-10
AU1137401A (en) 2001-05-08
DE60031790D1 (de) 2006-12-21
PE20010678A1 (es) 2001-07-04
IL149151A0 (en) 2002-11-10
MY129001A (en) 2007-03-30
HUP0203295A2 (hu) 2003-01-28
CN1201730C (zh) 2005-05-18
MXPA02003843A (es) 2002-09-30
US6300350B1 (en) 2001-10-09
EP1225878A1 (en) 2002-07-31
JP4074458B2 (ja) 2008-04-09
NO20021823D0 (no) 2002-04-18
EP1225878B1 (en) 2006-11-08
JO2178B1 (en) 2003-04-23
CZ20021657A3 (cs) 2002-10-16
JP2007302689A (ja) 2007-11-22
PL357499A1 (pl) 2004-07-26
BR0015225A (pt) 2002-07-16
JP2003512418A (ja) 2003-04-02
ZA200202576B (en) 2003-09-23
NZ518118A (en) 2004-02-27
CA2387844C (en) 2009-04-14
CN1382042A (zh) 2002-11-27
RU2257383C2 (ru) 2005-07-27
JP4850791B2 (ja) 2012-01-11
NO20021823L (no) 2002-04-18
AU777325B2 (en) 2004-10-14
DK1225878T3 (da) 2007-03-05
AR029648A1 (es) 2003-07-10
CY1105941T1 (el) 2011-04-06
CA2387844A1 (en) 2001-05-03
DE60031790T2 (de) 2007-09-20
WO2001030326A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
JP4850791B2 (ja) Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療
CN115916184A (zh) 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂
JPH013193A (ja) 細胞、組織修復剤
JP2011528355A (ja) 充血除去剤およびコルチコステロイドを含む鼻腔内粗製物
US6339107B1 (en) Methods for treatment of Emphysema using 13-cis retinoic acid
AU735382B2 (en) Use of alpha-rar antagonists for inhibition of mucin secretion
AU2007223469B2 (en) Method and composition for treating chronic obstructive pulmonary disease
JP2024520650A (ja) 特発性肺線維症の処置におけるカプサイシン誘導体
Burstein Prostaglandins and Cannabis—IV: A Biochemical Basis for Therapeutic Applications
MXPA00008580A (en) Use of alpha-rar antagonists for inhibition of mucin secretion
HK1051002B (en) Treatment of emphysema using rar selective retinoid agonists